Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer

Clinical Cancer Research

Volumn 3, Issue 9, 1997, Pages 1643-1651

  Newby, Jacqueline C ^a,b   Johnston, Stephen R D ^a   Smith, Ian E ^a   Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; DRUG RESISTANCE; ENZYME ACTIVITY; ESTROGEN BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOGENE C ERB; PREDICTION; PRIORITY JOURNAL; RECURRENT CANCER; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0030860567     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Johnston, S. R. D., Haynes, B. P., Smith, I. E., Jarman, M., Sacks, N. P. M., Ebbs, S. R., and Dowsett, M. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoural drug concentration. Lancet, 342: 1521-1522, 1993.
2. Wiebe, V. J., Osborne, C. K., McGuire, W. L., and DeGregorio, M. W. Identification of oestrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumours. J. Clin. Oncol., 10: 990-994, 1992.
3. Rose, C., Thorpe, S. M., Anderson, K. W., Pedersen, P. V., Mouridsen, H. T., Blichert-Toft, M., and Rasmussen, B. B. Beneficial effect of tamoxifen in primary breast cancer patients with high oestrogen receptor values. Lancet, 1: 16-18, 1985.
4. Fuqua, S. A. W., Fitzgerald, S. D., Chamness, G. C., Tandon, A. K., McDonnel, D., Nawaz, Z., O'Malley, B. W., and McGuire, W. L. Variant human breast oestrogen receptor with constitutive transcriptional activity. Cancer Res., 51: 105-109, 1991.
5. Prigent, S. A., and Lemoine, N. R. The type I (EGFR related) family of growth factor receptors and their ligands. Prog. Growth Factor Res., 4: 1-24, 1992.
6. Lupu, R., Colomer, R., Kannan, B., and Lippman, M. E. Characterization of a growth factor which binds exclusively to the erbB-2 receptor and induces cellular responses. Proc. Natl. Acad. Sci. USA, 89: 2287-2291, 1992.
7. Kern, F. G., Cheville, A. L., and Liu, Y. Growth factor receptors and the progression of breast cancer. Semin. Cancer Biol., 1: 317-328, 1990.
8. Saeki, T., Cristiano, A., Lynch, M. J., Brattain, M., Kim, N., Normanno, N., Kenney, N., Ciardiello, F., and Salomon, D. S. Regulation by oestrogen through the 5′-flanking region of the transforming growth factor a gene. Mol. Endocrinol., 5: 1955-1963, 1991.
9. Dickson, R. B., McManaway, M. E., and Lippman, M. E. Oestrogen-induced factors of breast cancer cells partially replace estrogen to promote tumour growth. Science (Washington), 232: 1540-1543, 1986.
10. Ahmed, S. R., Badger, B., Wright, C., and Manni, A. Role of transtorming growth factor-α in basal and hormone-stimulated growth by estradiol, prolactin and progesterone in human and rat mammary tumour cells: studies using TGF-α and EGF receptor antibodies. J. Steroid Biochem., 38: 687-693, 1991.
11. Manni, A., Wright, C., Badger, B., Bartholomew, M., Herlyn, M., Mendelsohn, J., Masui, H., and Demers, L. Role of transforming growth factor-α related peptides in the autocrine/paracrine control of experimental breast cancer growth in vitro by estradiol, prolactin and progesterone. Breast Cancer Res. Treat., 15: 73-83, 1990.
12. Kenney, N. J., Saeki, T., Gottardis, M., Kim, N., Garcia-Morales, P., Martin, M. B., Normanno, N., Ciardiello, F., Day, A., Cutler, M. L., and Salomon, D. S. Transforming growth factor α antisense mRNA blocks oestrogen-mediated growth and TGFα secretion in MCF-7 and ZR-75-1 human breast cancer cells. J. Cell. Physiol., 156: 497-514, 1993.
13. Reddy, K. B,. Mangold, G. L., Tandon, A. K., Yoneda, T., Mundy, G. R., Zilberstein, A., and Osborne, C. K. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res., 52: 3636-3641, 1992.
14. Berthois, Y., Dong, X. F., and Martin, P. M. Regulation of epidermal growth factor receptor by oestrogen and antioestrogen in the human breast cancer cell line MCF-7. Biochem. Biophys. Res. Commun., 159: 126-131, 1989.
15. Russell, K. S., and Hung, M-C. Transcriptional repression of the neu protooncogene by oestrogen stimulated oestrogen receptor. Cancer Res., 52: 6624-6629, 1992.
16. Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and de Bortoli, M. Inhibition of c-erbB2 oncogene expression by oestrogens in human breast cancer cells. Oncogene, 5: 1001-1006, 1990.
17. Read, L., Keith, D., Slamon, D. J., and Katzenellenbogen, B. S. Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res., 50: 3947-3951, 1990.
18. Liu, Y., El-Ashry, D., Chen, D., Ding, I. Y. F., and Kern, F. G. MCF-7 breast cancer cells overexpressing transfected c-erbB2 have and in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res. Treat., 34: 97-117, 1995.
19. Long, B., McKibben, B. M., Lynch, M., and van den Berg, H. W. Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer line. Br. J. Cancer, 65: 865-869, 1992.
20. Sainsbury, J. R. C., Farndon, J. R., Sherbet, V. G., and Harris, A. L. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet, i: 364-366, 1985.
21. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
22. Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. E., Troner, B., and Hynes, N. E. Correlation of c-erbB2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res., 48: 1238-1243, 1988.
23. Sainsbury, J. R. C., Farndon, J. R., Needham, G. K., Malcolm, A. J., and Harris, A. L. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet, i: 1398-1402, 1987.
24. Gullick, W. J., Love, S. B., Wright, C., Barnes, D. M., Gusterson, B., Harris, A. L., and Altman, D. G. c-erbB2 protein over-expression in human breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br. J. Cancer, 63: 434-438, 1990.
25. Klijn, J. G. M., Berns, P. M. J. J., Schmitz, P. I. M., and Foekens, J. A. The clinical significance of epidermal growth factor receptor in human breast cancer: review of 5232 patients. Endocr. Rev., 13: 3-17, 1992.
26. Wright, C., Nicholson, S., Angus, B., Sainsbury, J. R. C., Farndon, J., Cairns, J., Harris, A. L., and Home, C. Relationship between c-erbB2 protein expression and response to endocrine therapy in advanced breast cancer. Br. J. Cancer, 65: 1188-1121, 1992.
27. Harris, A. L., Nicholson, S., Sainsbury, J. R. C., Farndon, J., and Wright, C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J. Steroid Biochem., 34: 123-133, 1989.
28. Nicholson, R. I., McClelland, R. A., Gee, J. M. W., Manning, D. L., Cannon, P., Robertson, J. F. R., Ellis, I. O., and Blamey, R. W. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res. Treat., 29: 117-125, 1994.
29. Nicholson, S., Halcrow, P., Sainsbury, J. R. C., Angus, B., Chambers, B., Farndon, J., and Harris, A. L. Epidermal growth factor receptor status associated with failure of primary endocrine therapy in elderly post-menopausal patients with breast cancer. Br. J. Cancer, 58: 810-814, 1988.
30. Nicholson, R. I., McClelland, R. A., Finlay, P., Eaton, C. L., Gullick, W. J., Dixon, A. R., Robertson, J. F. R., Ellis, I. O., and Blarney, R. W. Relationship between EGFR, c-erbB2 protein expression and Ki 67 immunostaining in breast cancer and hormone sensitivity. Eur. J. Cancer, 29A: 1018-1023, 1993.
31. Archer, S. T., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I. O., Blamey, R. W., Nicholson, R. I., and Robertson, J. F. R. Expression of ras p21, p53 and c-erbB2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer, 72: 1259-1266, 1995.
32. Gusterson, B., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C-M., Goloum, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A. M. Burki, K., Castiglione, M., Collins, J., Lintner, J., and Senn, H-J. Prognostic importance of c-erbB2 expression in breast cancer. J. Clin. Oncol., 10: 1049-1056, 1992.
33. Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H., Ryden, S., and Sigurdsson, H. erbB-2 amplification is associated with tamoxifen resistance in steroid receptor positive breast cancer. Cancer Lett., 81: 137-144, 1994.
34. Johnston, S. R. D., Saccani-Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M., Ebbs, S. R., and Dowsett, M. Changes in oestrogen receptor, progesterone receptor and pS2 expression in tamoxifen resistant human breast cancer. Cancer Res., 55: 3331-3338, 1995.
35. Hayward, J. L., Carbonne, P. P., Heuston, J. C., Kumaoka, S., and Rubens, R. Assessment of response to therapy in advanced breast cancer. Cancer (Phila.), 39: 1289-1293, 1977.
36. Saccani-Jotti, G., Johnston, S. R. D., Salter, J., Detre, S., and Dowsett, M. Comparison of a new immunohistochemical assay for oestrogen receptor in paraffin embedded breast carcinomas with quantitative immunoassay. J. Clin. Pathol., 47: 900-905, 1994.
37. Andersen, J., Orntoft, T. F., and Poulsen, H. S. Immunohistochemical demonstration of oestrogen receptors in formalin-fixed, paraffin-embedded human breast cancer by use of a monoclonal antibody to the oestrogen receptor. J. Histochem. Cytochem., 36: 1553-1560, 1988.
38. Newby, J. C., A'Hern, R. P., Leek, R. D., Smith, I. E., Harris, A. L., and Dowsett, M. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand binding assay and clinical relevance in human breast cancer. Br. J. Cancer, 71: 1237-1242, 1995.
39. Tetu, B., and Brisson, J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer (Phila.), 73: 2359-2365, 1994.
40. Goldman, R., Levy, R. B., Peles, E., and Yarden, Y. Heterodimerisation of the erbB1 and erbB2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 29: 11024-11028, 1990.
41. Carraway, K. L., and Cantley, L. C. A Neu acquaintance for ErbB3 and ErbB4: a role for receptor heterodimerisation in growth signalling. Cell, 78: 5-85, 1994.
42. Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., DiFiore, P. P., and Kraus, M. H. Co-operative signalling of erbB3 and erbB4 in neoplastic transformation and human mammary carcinomas. Oncogene, 10: 1813-1821, 1995.
43. Yarden, R. I., Lauber, A. H., El-Ashry, D., and Chrysogelos, S. A. Bimodal regulation of epidermal growth factor receptor by oestrogen in breast cancer cells. Endocrinology, 137: 2739-2747, 1996.
44. Johnston, S. R. D., McLennan, K. A., Salter, J., Sacks, N. M., McKinna, J. A., Baum, M., Smith, I. E., and Dowsett, M. Tamoxifen induces the expression of cytoplasmic c-erbB2 immunoreactivity in ER positive breast carcinomas in vivo. Breast, 2: 93-99, 1993.